Fullerton Fund Management Co Ltd. Purchases 6,426 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Fullerton Fund Management Co Ltd. grew its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXXGet Rating) by 57.1% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 17,676 shares of the company’s stock after acquiring an additional 6,426 shares during the quarter. Fullerton Fund Management Co Ltd.’s holdings in IDEXX Laboratories were worth $11,639,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. EverSource Wealth Advisors LLC bought a new stake in IDEXX Laboratories in the fourth quarter worth $28,000. Bell Investment Advisors Inc bought a new stake in IDEXX Laboratories in the third quarter worth $34,000. Exane Derivatives bought a new stake in IDEXX Laboratories in the fourth quarter worth $40,000. Migdal Insurance & Financial Holdings Ltd. bought a new stake in IDEXX Laboratories in the third quarter worth $42,000. Finally, Sageworth Trust Co of South Dakota bought a new stake in IDEXX Laboratories in the fourth quarter worth $47,000. Hedge funds and other institutional investors own 84.92% of the company’s stock.

IDXX traded up $7.40 on Friday, hitting $372.23. The company had a trading volume of 768,216 shares, compared to its average volume of 972,493. The stock has a fifty day moving average price of $472.52 and a 200-day moving average price of $534.87. IDEXX Laboratories, Inc. has a 12-month low of $330.66 and a 12-month high of $706.95. The company has a debt-to-equity ratio of 1.21, a quick ratio of 0.81 and a current ratio of 1.12. The stock has a market capitalization of $31.27 billion, a price-to-earnings ratio of 43.64, a P/E/G ratio of 2.32 and a beta of 1.10.

IDEXX Laboratories (NASDAQ:IDXXGet Rating) last issued its quarterly earnings results on Wednesday, May 4th. The company reported $2.27 earnings per share for the quarter, topping analysts’ consensus estimates of $2.25 by $0.02. IDEXX Laboratories had a return on equity of 103.70% and a net margin of 22.43%. The business had revenue of $836.55 million for the quarter, compared to analyst estimates of $836.47 million. During the same quarter in the previous year, the firm earned $2.35 earnings per share. The company’s revenue was up 7.6% on a year-over-year basis. Analysts forecast that IDEXX Laboratories, Inc. will post 8.24 EPS for the current fiscal year.

IDXX has been the subject of several research analyst reports. Atlantic Securities initiated coverage on IDEXX Laboratories in a research report on Tuesday, February 8th. They set an “overweight” rating and a $650.00 target price for the company. StockNews.com downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Friday, May 6th. William Blair reiterated an “outperform” rating on shares of IDEXX Laboratories in a research report on Wednesday, February 2nd. Bank of America downgraded IDEXX Laboratories from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $550.00 to $470.00 in a research report on Thursday, May 5th. Finally, The Goldman Sachs Group decreased their target price on IDEXX Laboratories from $615.00 to $530.00 and set a “neutral” rating for the company in a research report on Thursday. Four equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $650.33.

About IDEXX Laboratories (Get Rating)

IDEXX Laboratories, Inc develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; LPD; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community.

Featured Articles

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.